West Pharmaceutical Services, Inc. (NYSE:WST) Shares Purchased by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC boosted its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 8.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,301 shares of the medical instruments supplier’s stock after purchasing an additional 105 shares during the period. Elevated Capital Advisors LLC’s holdings in West Pharmaceutical Services were worth $391,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in shares of West Pharmaceutical Services in the first quarter worth $27,000. Crewe Advisors LLC grew its stake in shares of West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in shares of West Pharmaceutical Services in the third quarter worth $30,000. ORG Partners LLC grew its stake in shares of West Pharmaceutical Services by 820.0% in the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after acquiring an additional 123 shares in the last quarter. Finally, Quest Partners LLC grew its stake in shares of West Pharmaceutical Services by 5,633.3% in the second quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after acquiring an additional 169 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $286.44 on Thursday. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average price of $299.72 and a 200 day moving average price of $323.06. The company has a market cap of $20.78 billion, a P/E ratio of 40.75, a PEG ratio of 10.21 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The business’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.11 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.